2. Others
  3. Drug Isomer
  4. 2682850-41-3

2682850-41-3

RIP1/RIP3/MLKL activator 1 Chemical Structure

2682850-41-3

Chemical Structure

  • RIP1/RIP3/MLKL activator 1
  • CAS No: 2682850-41-3
    Formula: C43H56N4O3
    Molecular Weight: 676.93
  • IUPAC Name: (2R,4aS,6aS,12bR,14aS)-N-((1-(4-(tert-butyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxamide
  • InChIKey: QLFCJGYFBTYJGC-RSWNTZNOSA-N
  • SMILES: CC1=C(C(C=C2C1=CC=C3[C@]4(CC[C@]5(CC[C@@](C(NCC6=CN(N=N6)CC7=CC=C(C=C7)C(C)(C)C)=O)(CC5[C@@]4(CC[C@@]23C)C)C)C)C)=O)O

Biological Activity: RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability[1].

Cat. No. Product Name Purity Description
HY-144828 RIP1/RIP3/MLKL activator 1 ≥97.0% RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability.

References

[1]. Yao Feng, et al. Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis. Eur J Med Chem. 2022 Feb 5;229:114070. [Content Brief]

Keywords:

RIP1/RIP3/MLKL activator 1